IBDEI15Y ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18883,1,3,0)
 ;;=3^Sicca Syndrome w/ Myopathy
 ;;^UTILITY(U,$J,358.3,18883,1,4,0)
 ;;=4^M35.03
 ;;^UTILITY(U,$J,358.3,18883,2)
 ;;=^5011789
 ;;^UTILITY(U,$J,358.3,18884,0)
 ;;=M35.09^^64^841^57
 ;;^UTILITY(U,$J,358.3,18884,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18884,1,3,0)
 ;;=3^Sicca Syndrome w/ Oth Organ Involvement
 ;;^UTILITY(U,$J,358.3,18884,1,4,0)
 ;;=4^M35.09
 ;;^UTILITY(U,$J,358.3,18884,2)
 ;;=^5011791
 ;;^UTILITY(U,$J,358.3,18885,0)
 ;;=M35.04^^64^841^58
 ;;^UTILITY(U,$J,358.3,18885,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18885,1,3,0)
 ;;=3^Sicca Syndrome w/ Tubulo-Interstitial Nephropathy
 ;;^UTILITY(U,$J,358.3,18885,1,4,0)
 ;;=4^M35.04
 ;;^UTILITY(U,$J,358.3,18885,2)
 ;;=^5011790
 ;;^UTILITY(U,$J,358.3,18886,0)
 ;;=M35.00^^64^841^59
 ;;^UTILITY(U,$J,358.3,18886,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18886,1,3,0)
 ;;=3^Sicca Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,18886,1,4,0)
 ;;=4^M35.00
 ;;^UTILITY(U,$J,358.3,18886,2)
 ;;=^5011786
 ;;^UTILITY(U,$J,358.3,18887,0)
 ;;=M32.10^^64^841^62
 ;;^UTILITY(U,$J,358.3,18887,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18887,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec Organ/System Involvement
 ;;^UTILITY(U,$J,358.3,18887,1,4,0)
 ;;=4^M32.10
 ;;^UTILITY(U,$J,358.3,18887,2)
 ;;=^5011753
 ;;^UTILITY(U,$J,358.3,18888,0)
 ;;=M32.9^^64^841^61
 ;;^UTILITY(U,$J,358.3,18888,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18888,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec
 ;;^UTILITY(U,$J,358.3,18888,1,4,0)
 ;;=4^M32.9
 ;;^UTILITY(U,$J,358.3,18888,2)
 ;;=^5011761
 ;;^UTILITY(U,$J,358.3,18889,0)
 ;;=M34.2^^64^841^63
 ;;^UTILITY(U,$J,358.3,18889,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18889,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,18889,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,18889,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,18890,0)
 ;;=M34.81^^64^841^64
 ;;^UTILITY(U,$J,358.3,18890,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18890,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,18890,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,18890,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,18891,0)
 ;;=M34.82^^64^841^65
 ;;^UTILITY(U,$J,358.3,18891,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18891,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,18891,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,18891,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,18892,0)
 ;;=M34.83^^64^841^66
 ;;^UTILITY(U,$J,358.3,18892,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18892,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,18892,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,18892,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,18893,0)
 ;;=M34.9^^64^841^67
 ;;^UTILITY(U,$J,358.3,18893,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18893,1,3,0)
 ;;=3^Systemic Sclerosis,Unspec
 ;;^UTILITY(U,$J,358.3,18893,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,18893,2)
 ;;=^5011785
 ;;^UTILITY(U,$J,358.3,18894,0)
 ;;=J84.170^^64^841^16
 ;;^UTILITY(U,$J,358.3,18894,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18894,1,3,0)
 ;;=3^Interstitial Lung Dis w/ Progressive Fibrotic Phenotype in Dis Classd Elsewhere
 ;;^UTILITY(U,$J,358.3,18894,1,4,0)
 ;;=4^J84.170
 ;;^UTILITY(U,$J,358.3,18894,2)
 ;;=^5159208
 ;;^UTILITY(U,$J,358.3,18895,0)
 ;;=J84.178^^64^841^17
 ;;^UTILITY(U,$J,358.3,18895,1,0)
 ;;=^358.31IA^4^2
